Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barratt

Showing results (211-220 of 272) with videos related to

Pageof 28
Sort By:
Kidney International Reports|February 22, 2021
Epidemiology, baseline characteristics and risk of progression in the first South-Asian prospective longitudinal observational IgA nephropathy cohortSuceena Alexander, Santosh Varughese, Rajanbabu Franklin, et al.
Kidney International Reports|December 22, 2025
Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY TrialVlado Perkovic, Jonathan Barratt, Richard Lafayette, et al.
Kidney International Reports|February 14, 2022
Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy CohortSuceena Alexander, Santosh Varughese, Rajanbabu Franklin, et al.
Kidney International Reports|May 28, 2026
Zigakibart Potently Inhibits A Proliferation-Inducing Ligand-Mediated IgA Production, Addressing IgAN Pathogenesis Root CausesJohn Dulos, Joost Kreijtz, Paul Vink, et al.
Kidney International|September 20, 2025
Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Jürgen Floege, Jonathan Barratt, H Terence Cook, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 19, 2020
Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with <i>De Novo</i> Minimal Change Disease: A Multicenter, Randomized, Controlled TrialNicholas Rhys Medjeral-Thomas, Christopher Lawrence, Marie Condon, et al.
Molecular Systems Biology|January 4, 2024
Detection of PatIent-Level distances from single cell genomics and pathomics data with Optimal Transport (PILOT)Mehdi Joodaki, Mina Shaigan, Victor Parra, et al.
Kidney International|January 8, 2021
Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progressionIzabella Z A Pawluczyk, Athanasios Didangelos, Sean J Barbour, et al.
Lancet (London, England)|April 4, 2023
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trialHiddo J L Heerspink, Jai Radhakrishnan, Charles E Alpers, et al.
Lancet (London, England)|April 2, 2017
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trialBengt C Fellström, Jonathan Barratt, Heather Cook, et al.
Pageof 28

Showing results (211-220 of 272) with videos related to

Sort By:
Pageof 28
Kidney International Reports|February 22, 2021
Epidemiology, baseline characteristics and risk of progression in the first South-Asian prospective longitudinal observational IgA nephropathy cohortSuceena Alexander, Santosh Varughese, Rajanbabu Franklin, et al.
Kidney International Reports|December 22, 2025
Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY TrialVlado Perkovic, Jonathan Barratt, Richard Lafayette, et al.
Kidney International Reports|February 14, 2022
Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy CohortSuceena Alexander, Santosh Varughese, Rajanbabu Franklin, et al.
Kidney International Reports|May 28, 2026
Zigakibart Potently Inhibits A Proliferation-Inducing Ligand-Mediated IgA Production, Addressing IgAN Pathogenesis Root CausesJohn Dulos, Joost Kreijtz, Paul Vink, et al.
Kidney International|September 20, 2025
Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Jürgen Floege, Jonathan Barratt, H Terence Cook, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 19, 2020
Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with <i>De Novo</i> Minimal Change Disease: A Multicenter, Randomized, Controlled TrialNicholas Rhys Medjeral-Thomas, Christopher Lawrence, Marie Condon, et al.
Molecular Systems Biology|January 4, 2024
Detection of PatIent-Level distances from single cell genomics and pathomics data with Optimal Transport (PILOT)Mehdi Joodaki, Mina Shaigan, Victor Parra, et al.
Kidney International|January 8, 2021
Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progressionIzabella Z A Pawluczyk, Athanasios Didangelos, Sean J Barbour, et al.
Lancet (London, England)|April 4, 2023
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trialHiddo J L Heerspink, Jai Radhakrishnan, Charles E Alpers, et al.
Lancet (London, England)|April 2, 2017
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trialBengt C Fellström, Jonathan Barratt, Heather Cook, et al.
Pageof 28